The B7 family revisited

Annual Review of Immunology

Volumn 23, Issue , 2005, Pages 515-548

  Greenwald, Rebecca J ^a   Freeman, Gordon J ^b   Sharpe, Arlene H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

B7; CD28; Costimulation; Tolerance

Indexed keywords

B7 ANTIGEN; B7 DC ANTIGEN; B7 H1 ANTIGEN; B7 H3 ANTIGEN; B7 H4 ANTIGEN; BTLA RECEPTOR; CD28 ANTIGEN; CD4 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ICOS RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; LIGAND; PD 1 RECEPTOR; RECEPTOR; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANTIGEN FUNCTION; ANTIGEN PRESENTING CELL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ASTHMA; AUTOIMMUNITY; HUMANS; HYPERSENSITIVITY; INFECTION; MEMBRANE GLYCOPROTEINS; MICE; PROTEINS; TRANSPLANTATION IMMUNOLOGY;

EID: 17644425689     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.23.021704.115611     Document Type: Review

References (152)

1. Sharpe AH, Freeman GJ. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2:116-26
2. Khoury SJ, Sayegh MH. 2004. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 20:529-38
3. Chen LP. 2004. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4:336-47
4. Abbas AK. 2003. The control of T cell activation vs. tolerance. Autoimmun. Rev. 2:115-18
5. Carreno BM, Collins M. 2002. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol. 20:29-53
6. Chikuma S, Bluestone JA. 2003. CTLA-4 and tolerance: the biochemical point of view. Immunol. Res. 28:241-53
7. Coyle AJ, Gutierrez-Ramos JC. 2003. More negative feedback? Nat. Immunol. 4:647-48
8. Greenwald RJ, Latchman YE, Sharpe AH. 2002. Negative co-receptors on lymphocytes. Curr. Opin. Immunol. 14:391-96
9. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, et al. 1999. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397:263-66
10. Swallow MM, Wallin JJ, Sha WC. 1999. B7h, a novel costimulatory homolog of B7.1 andB7.2, is induced by TNF α. Immunity 11:423-32
11. Ling V, Wu PW, Finnerty HF, Bean KM, Spaulding V, et al. 2000. Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor. J. Immunol. 164:1653-57
12. Yoshinaga SK, Whoriskey JS, Khare SD, Sarmiento U, Guo J, et al. 1999. T-cell costimulation through B7RP-1 and ICOS. Nature 402:827-32
13. Brodie D, Collins AV, Iaboni A, Fennelly JA, Sparks LM, et al. 2000. LICOS, a primordial costimulatory ligand? Curr. Biol. 10:333-36
14. Wang SD, Zhu GF, Chapoval AI, Dong H, Tamada K, et al. 2000. Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS. Blood 96:2808-13
15. Ishida Y, Agata Y, Shibahara K, Honjo T. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887-95
16. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027-34
17. Dong HD, Zhu GF, Tamada K, Chen LP. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5:1365-69
18. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2:261-68
19. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, et al. 2001. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193:839-46
20. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, et al. 2001. B7-H3: a costimulatory molecule for T cell activation and IFN-γ production. Nat. Immunol. 2:269-74
21. Sica GL, Choi IH, Zhu GF, Tamada K, Wang SD, et al. 2003. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity 18:849-61
22. Zang XX, Loke P, Kim J, Murphy K, Waitz R, Allison JP. 2003. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl. Acad. Sci. USA 100:10388-92
23. Prasad DVR, Richards S, Mai XM, Dong C. 2003. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity 18:863-73
24. Watanabe N, Gavrieli M, Sedy JR, Yang JF, Fallarino F, et al. 2003. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4:670-79
25. Coyle AJ, Gutierrez-Ramos JC. 2001. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat. Immunol. 2:203-9
26. van der Merwe PA, Davis SJ. 2003. Molecular interactions mediating T cell antigen recognition. Annu. Rev. Immunol. 21:659-84
27. Taylor PA, Lees CJ, Fournier S, Allison JP, Sharpe AH, Blazar BR. 2004. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions. J. Immunol. 172:34-39
28. Paust S, Lu LR, McCarty N, Cantor H. 2004. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc. Natl. Acad. Sci. USA 101:10398-403
29. + regulatory T cells. J. Immunol. 171:3348-52
30. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, et al. 2002. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol 3:1097-101
31. Short JJ, Pereboev AV, Kawakami Y, Vasu C, Holterman MJ, Curiel DT. 2004. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 322:349-59
32. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, et al. 2004. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J. Clin. Invest. 113:1390-97
33. Vijayakrishnan L, Slavik JM, Illes Z, Greenwald RJ, Rainbow D, et al. 2004. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 20:563-75
34. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431-40
35. Lohr J, Knoechel B, Jiang S, Sharpe AH, Abbas AK. 2003. The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat. Immunol. 4:664-69
36. Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, et al. 2003. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4:1206-12
37. + T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol. 172:4100-10
38. Podojil JR, Kin NW, Sanders VM. 2004. CD86 and β2-adrenergic receptor signaling pathways, respectively, increase Oct-2 and OCA-B Expression and binding to the 3′-IgH enhancer in B cells. J. Biol. Chem. 279:23394-404
39. Podojil JR, Sanders VM. 2003. Selective regulation of mature IgG1 transcription by CD86 and β 2-adrenergic receptor stimulation. J. Immunol. 170:5143-51
40. Ueda H, Howson JM, Esposito L, Heward J, Snook H, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-11
41. Egen JG, Kuhns MS, Allison JP. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3:611-18
42. Coyle AJ, Lehar S, Lloyd C, Tian J, Delaney T, et al. 2000. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 13:95-105
43. Rudd CE, Schneider H. 2003. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 3:544-56
44. Beier KC, Hutloff A, Dittrich AM, Heuck C, Rauch A, et al. 2000. Induction, binding specificity and function of human ICOS. Eur. J. Immunol. 30:3707-17
45. Parry RV, Rumbley CA, Vandenberghe LH, June CH, Riley JL. 2003. CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. J. Immunol. 171:166-74
46. Okamoto N, Tezuka K, Kato M, Abe R, Tsuji T. 2003. PI3-kinase and MAP-kinase signaling cascades in AILIM/ICOS- and CD28-costimulated T-cells have distinct functions between cell proliferation and IL-10 production. Biochem. Biophys. Res. Commun. 310:691-702
47. Harada Y, Tanabe E, Watanabe R, Weiss BD, Matsumoto A, et al. 2001. Novel role of phosphatidylinositol 3-kinase in CD28-mediated costimulation. J. Biol. Chem. 276:9003-8
48. Riley JL, Blair PJ, Musser JT, Abe R, Tezuka K, et al. 2001. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. J. Immunol. 166:4943-48
49. Mages HW, Hutloff A, Heuck C, Buchner K, Himmelbauer H, et al. 2000. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur. J. Immunol. 30:1040-47
50. + T cells. J. Immunol. 165:5035-40
51. Kopf M, Coyle AJ, Schmitz N, Barner M, Oxenius A, et al. 2000. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection. J. Exp. Med. 192:53-61
52. Wassink L, Vieira PL, Smits HH, Kingsbury GA, Coyle AJ, et al. 2004. ICOS expression by activated human Th cells is enhanced by IL-12 and IL-23: increased ICOS expression enhances the effector function of both Th1 and Th2 cells. J. Immunol. 173:1779-86
53. Ogasawara K, Yoshinaga SK, Lanier LL. 2002. Inducible costimulator costimulates cytotoxic activity and IFN-γ production in activated murine NK cells. J. Immunol. 169:3676-85
54. + progenitor cells during differentiation into antigen presenting cells. J. Biol. Chem. 276:45686-93
55. Yoshinaga SK, Zhang M, Pistillo J, Horan T, Khare SD, et al. 2000. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS. Int. Immunol. 12:1439-47
56. Aicher A, Hayden-Ledbetter M, Brady WA, Pezzutto A, Richter G, et al. 2000. Characterization of human inducible costimulator ligand expression and function. J. Immunol. 164:4689-96
57. Nakazawa A, Dotan I, Brimnes J, Allez M, Shao L, et al. 2004. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology 126:1347-57
58. Wiendl H, Mitsdoerffer M, Schneider D, Melms A, Lochmuller H, et al. 2003. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible costimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 126:1026-35
59. Liang L, Porter EM, Sha WC. 2002. Constitutive expression of the B7h ligand for inducible costimulator on naive B cells is extinguished after activation by distinct B cell receptor and interleukin 4 receptor-mediated pathways and can be rescued by CD40 signaling. J. Exp. Med. 196:97-108
60. Sperling AI, Bluestone JA. 2001. ICOS costimulation: It's not just for TH2 cells anymore. Nat. Immunol. 2:573-74
61. + effector T cells with high inflammatory potential and a strong bias for secretion of interleukin 10. J. Exp. Med. 197:181-93
62. Villegas EN, Lieberman LA, Mason N, Blass SL, Zediak VP, et al. 2002. A role for inducible costimulator protein in the CD28-independent mechanism of resistance to Toxoplasma gondii. J. Immunol. 169:937-43
63. Kanai T, Totsuka T, Tezuka K, Watanabe M. 2002. ICOS costimulation in inflammatory bowel disease. J. Gastroenterol. 37(Suppl. 14):78-81
64. Akbari O, Freeman GJ, Meyer EH, Greenfield EA, Chang TT, et al. 2002. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 8:1024-32
65. + Th cells produce distinct cytokines in different mucosal immune responses. Eur. J. Immunol. 33:392-401
66. Nurieva RI, Duong J, Kishikawa H, Dianzani U, Rojo JM, et al. 2003. Transcriptional regulation of th2 differentiation by inducible costimulator. Immunity 18:801-11
67. Nurieva RI, Mai XM, Forbush K, Bevan MJ, Dong C. 2003. B7h is required for T cell activation, differentiation, and effector function. Proc. Natl. Acad. Sci. USA 100:14163-68
68. McAdam AJ, Greenwald RJ, Levin MA, Chernova T, Malenkovich N, et al. 2001. ICOS is critical for CD40-mediated antibody class switching. Nature 409:102-5
69. Tafuri A, Shahinian A, Bladt F, Yoshinaga SK, Jordana M, et al. 2001. ICOS is essential for effective T-helper-cell responses. Nature 409:105-9
70. Suh WK, Gajewska BU, Okada H, Gronski MA, Bertram EM, et al. 2003. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat. Immunol. 4:899-906
71. Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, et al. 2003. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat. Immunol. 4:261-68
72. Suh WK, Tafuri A, Berg-Brown NN, Shahinian A, Plyte S, et al. 2004. The inducible costimulator plays the major costimulatory role in humoral immune responses in the absence of CD28. J. Immunol. 172:5917-23
73. Sporici RA, Beswick RL, von Allmen C, Rumbley CA, Hayden-Ledbetter M, et al. 2001. ICOS ligand costimulation is required for T-cell encephalitogenicity. Clin. Immunol. 100:277-88
74. Rottman JB, Smith T, Tonra JR, Ganley K, Bloom T, et al. 2001. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat. Immunol. 2:605-11
75. Dong C, Nurieva RI. 2003. Regulation of immune and autoimmune responses by ICOS. J. Autoimmun. 21:255-60
76. Iwai H, Kozono Y, Hirose S, Akiba H, Yagita H, et al. 2002. Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation. J. Immunol. 169:4332-39
77. Nurieva RI, Treuting P, Duong J, Flavell RA, Dong C. 2003. Inducible costimulator is essential for collagen-induced arthritis. J. Clin. Invest. 111:701-6
78. Okamoto T, Saito S, Yamanaka H, Tomatsu T, Kamatani N, et al. 2003. Expression and function of the co-stimulator H4/ICOS on activated T cells of patients with rheumatoid arthritis. J. Rheumatol. 30:1157-63
79. Greve B, Vijayakrishnan L, Kubal A, Sobel RA, Peterson LB, et al. 2004. The diabetes susceptibility locus Idd5.1 on mouse chromosome 1 regulates ICOS expression and modulates murine experimental autoimmune encephalomyelitis. J. Immunol. 173:157-63
80. + T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J. Exp. Med. 199:1479-89
81. Coyle AJ, Gutierrez-Ramos JC. 2004. The role of ICOS and other costimulatory molecules in allergy and asthma. Springer Semin. Immunopathol. 25:349-59
82. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, et al. 2001. ICOS costimulatory receptor is essential for T-cell activation and function. Nature 409:97-101
83. Gonzalo JA, Tian J, Delaney T, Corcoran J, Rottman JB, et al. 2001. ICOS is critical for T helper cell-mediated lung mucosal inflammatory responses. Nat. Immunol. 2:597-604
84. Tesciuba AG, Subudhi S, Rother RP, Faas SJ, Frantz AM, et al. 2001. Inducible costimulator regulates Th2-mediated inflammation, but not Th2 differentiation, in a model of allergic airway disease. J. Immunol. 167:1996-2003
85. Mittrucker HW, Kursar M, Kohler A, Yanagihara D, Yoshinaga SK, Kaufmann SH. 2002. Inducible costimulator protein controls the protective T cell response against Listeria monocytogenes. J. Immunol. 169:5813-17
86. Greenwald RJ, McAdam AJ, Van der Woude D, Satoskar AR, Sharpe AH. 2002. Cutting edge: inducible costimulator protein regulates both Th1 and Th2 responses to cutaneous leishmaniasis. J. Immunol. 168:991-95
87. Miyahira Y, Akiba H, Ogawa SH, Ishi T, Watanabe S, et al. 2003. Involvement of ICOS-B7RP-1 costimulatory pathway in the regulation of immune responses to Leishmania major and Nippostrongylus brasiliensis infections. Immunol. Lett. 89:193-99
88. Rutitzky LI, Ozkaynak E, Rottman JB, Stadecker MJ. 2003. Disruption of the ICOS-B7RP-1 costimulatory pathway leads to enhanced hepatic immunopathology and increased γ interferon production by CD4 T cells in murine schistosomiasis. Infect. Immun. 71:4040-44
89. Cause WC, Chen SJ, Greenwald RJ, Halvorson MJ, Lu P, et al. 1997. CD28 dependence of T cell differentiation to IL-4 production varies with the particular type 2 immune response. J. Immunol. 158:4082-87
90. Bertram EM, Tafuri A, Shahinian A, Chan VS, Hunziker L, et al. 2002. Role of ICOS versus CD28 in antiviral immunity. Eur. J. Immunol. 32:3376-85
91. + T lymphocytes. Virology 325:252-63
92. Rothstein DM, Sayegh MH. 2003. T-cell costimulatory pathways in allograft rejection and tolerance. Immunol Rev. 196:85-108
93. Ozkaynak E, Gao W, Shemmeri N, Wang C, Gutierrez-Ramos JC, et al. 2001. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat. Immunol. 2:591-96
94. Kosuge H, Suzuki J, Gotoh R, Koga N, Ito H, et al. 2003. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 75:1374-79
95. Nanji SA, Hancock WW, Anderson CC, Adams AB, Luo B, et al. 2004. Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am. J. Transplant. 4:526-36
96. Salama AD, Yuan X, Nayer A, Chandraker A, Inobe M, et al. 2003. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. Am. J. Transplant. 3:390-95
97. Vibhakar R, Juan G, Traganos F, Darzynkiewicz Z, Finger LR. 1997. Activation-induced expression of human programmed death-1 gene in T-lymphocytes. Exp. Cell. Res. 232:25-28
98. Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T. 1994. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 23:704-6
99. Zhang XW, Schwartz JCD, Guo XL, Bhatia S, Cao EH, et al. 2004. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20:337-47
100. Shlapatska LM, Mikhalap SV, Berdova AG, Zelensky OM, Yun TJ, et al. 2001. CD150 association with either the SH2-containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is regulated by the adaptor protein SH2D1A. J. Immunol 166:5480-87
101. Nishimura H, Honjo T, Minato N. 2000. Facilitation of β selection and modification of positive selection in the thymus of PD-1-deficient mice. J. Exp. Med. 191:891-98
102. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, et al. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8:765-72
103. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. 2001. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA 98:13866-71
104. Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, et al. 2003. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33:2706-16
105. + T cell activation and cytolysis. Eur. J. Immunol 33:3117-26
106. Petroff MG, Chen LP, Phillips TA, Azzola D, Sedlmayr P, Hunt JS. 2003. B7 family molecules are favorably positioned at the human maternal-fetal interface. Biol. Reprod. 68:1496-504
107. Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman GJ, et al. 2002. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 84:57-62
108. Loke P, Allison JP. 2003. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA 100:5336-41
109. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173:945-54
110. + T cells and is overcome by IL-2. Eur. J. Immunol. 32:634-43
111. Tamura H, Dong H, Zhu G, Sica GL, Flies DB, et al. 2001. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 97:1809-16
112. Wang SD, Bajorath J, Flies DB, Dong HD, Honjo T, Chen LP. 2003. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J. Exp. Med. 197:1083-91
113. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-51
114. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, et al. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319-22
115. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, et al. 2003. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9:1477-83
116. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, et al. 2003. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198:63-69
117. Luhder F, Hoglund P, Allison JP, Benoist C, Mathis D. 1998. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187:427-32
118. Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, et al. 2004. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J. Clin. Invest. 113:694-700
119. Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, et al. 2003. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198:71-78
120. Latchman YE, Liang SC, Wu Y, Chernova T, Sobel RA, et al. 2004. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl. Acad. Sci. USA 101:10691-96
121. Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, et al. 2003. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J. Immunol. 171:4156-63
122. + T lymphocytes. Immunity 20:327-36
123. + T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J. Rheumatol. 30:1410-19
124. Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, et al. 2002. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat. Genet. 32:666-69
125. Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST. 2003. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62:492-97
126. Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, et al. 2003. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J. Clin. Invest. 111:363-70
127. Matsumoto K, Inoue H, Nakano T, Tsuda M, Yoshiura Y, et al. 2004. B7-DC regulates asthmatic response by an IFN-γ-dependent mechanism. J. Immunol. 172:2530-41
128. Iwai Y, Terawaki S, Ikegawa M, Okazaki T, Honjo T. 2003. PD-I inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198:39-50
129. Smith P, Walsh CM, Mangan NE, Fallon RE, Sayers JR, et al. 2004. Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages. J. Immunol. 173:1240-48
130. Ozkaynak E, Wang L, Goodearl A, McDonald K, Qin S, et al. 2002. Programmed death-1 targeting can promote allograft survival. J. Immunol. 169:6546-53
131. Gao W, Demirci G, Strom TB, Li XC. 2003. Stimulating PD-1-negative signals concurrent with blocking CD154 costimulation induces long-term islet allograft survival. Transplantation 76:994-99
132. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, et al. 2003. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J. Immunol. 171:1272-77
133. Aramaki O, Shirasugi N, Takayama T, Shimazu M, Kitajima M, et al. 2004. Programmed death-1-programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen. Transplantation 77:6-12
134. + T cells. Cancer Res. 64:1140-45
135. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. 2002. Tumor- associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793-800
136. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, et al. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 170:1257-66
137. Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen LP, et al. 2003. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 63:7462-67
138. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, et al. 2003. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198:851-62
139. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99:12293-97
140. Curiel TJ, Wei S, Dong HD, Alvarez X, Cheng P, et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562-67
141. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, et al. 2003. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63:6501-5
142. Liu XL, Gao JX, Wen J, Yin LJ, Li O, et al. 2003. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J. Exp. Med. 197:1721-30
143. Radhakrishnan S, Nguyen LT, Ciric B, Flies D, Van Keulen VP, et al. 2004. Immunotherapeutic potential of B7-DC (PD-L2) cross-linking antibody in conferring antitumor immunity. Cancer Res. 64:4965-72
144. Sun MY, Richards S, Prasad DVR, Mai XM, Rudensky A, Dong C. 2002. Characterization of mouse and human B7-H3 genes. J. Immunol. 168:6294-97
145. Steinberger P, Majdic O, Derdak SV, Pfistershammer K, Kirchberger S, et al. 2004. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J. Immunol 172:2352-59
146. Ling V, Wu PW, Spaulding V, Kieleczawa J, Luxenberg D, et al. 2003. Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics 82:365-77
147. Ferlazzo G, Semino C, Meta M, Procopio F, Morandi B, Melioli G. 2002. T lymphocytes express B7 family molecules following interaction with dendritic cells and acquire bystander costimulatory properties. Eur. J. Immunol. 32:3092-101
148. Saatian B, Yu XY, Lane AP, Doyle T, Casolaro V, Spannhake EW. 2004. Expression of genes for B7-H3 and other T cell ligands by nasal epithelial cells during differentiation and activation. Am. J. Physiol. Lung Cell. Mol. Physiol. 287:L217-25
149. Sun X, Vale M, Leung E, Kanwar JR, Gupta R, Krissansen GW. 2003. Mouse B7-H3 induces antitumor immunity. Gene Ther. 10:1728-34
150. Choi IH, Zhu G, Sica GL, Strome SE, Cheville JC, et al. 2003. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J. Immunol. 171:4650-54
151. Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM. 2003. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. Biophys. Res. Commun. 312:1236-43
152. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, et al. 2004. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol. 6:90-98